**1. Sanofi completes Dynavax acquisition (Feb 10) -- Paul Hudson making AI-forward moves**
Sanofi closed the Dynavax deal, adding HEPLISAV-B (hep B vaccine) and a shingles candidate. Hudson published a Fortune piece on Feb 10 positioning Sanofi as the AI-first pharma company: 10 new drug targets discovered in one year via ML, 65% improveme
- [Sanofi completes Dynavax acquisition](https://www.globenewswire.com/news-release/2026/02/10/3235419/0/en/Press-Release-Sanofi-completes-the-acquisition-of-Dynavax.html)
- [Hudson on AI reshaping pharma](https://fortune.com/2026/02/10/sanofi-ceo-paul-hudson-predictions-2026-ai-transformation/)
- [Venglustat Phase 3 success in Type 3 Gaucher](https://www.statnews.com/2026/02/02/sanofi-venglustat-gaucher-rare-disease-neurological-symptoms/)
- [Rilzabrutinib FDA Breakthrough in warm AIHA](https://www.pharmabiz.com/NewsDetails.aspx?aid=184157&sid=2)
**2. Victor Bulto (Novartis US) quoted on radiopharmaceuticals, now on Labcorp board**
Bulto was quoted Feb 9 on Novartis's radiopharmaceutical strategy ("What we are doing has activated the whole space"). He also joined Labcorp's board in Dec 2025. Both signal he remains highly active and visible -- good timing for Andrea Marazzi foll